



130254001M: 100 tests/kit
130654001M: 50 tests/kit
130754001M: 30 tests/kit

MAGLUMI® β2-Microglobulin (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of β2-Microglobulin (β2-MG) in human serum, plasma and urine using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in the diagnosis of kidney disease and lymphoproliferative diseases such as multiple myeloma.

SUMMARY

β2-microglobulin is a small protein with a molecular weight of 11800 daltons. It is synthesised by most nucleated cells, is present on their surfaces, and is closely associated with immunoglobulins and cell-surface histocompatibility antigens¹. Its circulating pool in plasma and other body fluids is derived largely from the shedding of this protein from the surfaces of nucleated cells, where it is normally noncovalently associated with other molecules, most notably class I histocompatibility antigens².

Ninety-five percent of the excretion of β2-MG is carried out by the kidney. It is almost completely reabsorbed by the proximal tubules where it is degraded into its component amino acids². Increased β2-MG excretion is association with renal diseases characterized by tubular damage¹. Measurement of β2-MG in urine is a sensitive assay to detect tubular injury, and strongly correlated with CD133 staining in injured renal proximal tubules³. β2-MG, a novel marker of kidney function, predicts mortality and kidney failure in the general population, and its elevation following transplantation is a marker of acute rejection⁴. Serum β2-MG used alone or together with urine β2-MG appears a promising supplement to clearance techniques for estimation of glomerular filtration as well as tubular function in the transplanted kidney⁵. β2-MG estimation may be used to distinguish between upper and lower urinary-tract infections, except when pre-existing tubular damage is present¹. Increased serum values in the presence of a normal GFR indicate increased β2-MG production. This has been observed in lymphoproliferative diseases, autoimmune diseases (SLE, RA), immune system associated diseases (Crohn's disease, chronic hepatitis, sarcoidosis, vasculitis), in patients with AIDS and in some malignant diseases like Hodgkin's disease, non-Hodgkin lymphoma, leukemia and in multiple myeloma^{6,7}. Serum levels may also be increased in renal diseases that diminish glomerular filtration and/or tubular reabsorption, chronic inflammatory diseases, and in malignancies such as multiple myeloma in which its synthesis is increase⁴. Infectious mononucleosis and cytomegalovirus were associated with pronounced increases of β2-MG concentration in serum⁸. The plasma level of this protein is elevated in patients who have undergone dialysis for a prolonged period². In humans, chronic hypokalemia results in tubulointerstitial injury, which may lead to proximal tubular dysfunction. Emery et al. found that 45% of patients with hypokalemia showed increased urinary excretion of β2-MG, which was reversible with potassium supplementation⁹. The urinary concentration of β2-MG was significantly increased in acute pyelonephritis compared with acute cystitis and asymptomatic bacteriuria¹⁰.

TEST PRINCIPLE

Competitive chemiluminescence immunoassay.

The sample, ABEI labeled with β2-MG monoclonal antibody, FITC labeled with β2-MG antigen and magnetic microbeads coated with FITC antibody are mixed thoroughly and incubated. β2-MG present in the sample compete with β2-MG antigen labeled with FITC for binding β2-MG monoclonal antibody labeled with ABEI, forming immuno-complexes. The complexes are finally binding with magnetic microbeads coated with FITC antibody. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is inversely proportional to the concentration of β2-MG present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with FITC antibody (~33.3 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	2.5 mL	1.5 mL	1.0 mL
Calibrator Low	A low concentration of β2-MG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Calibrator High	A high concentration of β2-MG antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
FITC Label	FITC labeled with β2-MG antigen (~62.5 ng/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	9.5 mL	5.5 mL	3.9 mL
ABEI Label	ABEI labeled with β2-MG monoclonal antibody (~45.5 ng/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	10.5 mL	6.0 mL	4.2 mL
Diluent	0.9% NaCl.	5.5 mL	3.5 mL	3.5 mL
Control 1	A low concentration of β2-MG antigen (2.00 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Control 2	A high concentration of β2-MG antigen (6.00 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
All reagents are provided ready-to-use.				

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay.
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handing during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.
- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks
On-board	4 weeks

Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 10-30°C	6 hours
Opened at 2-8°C	6 weeks
Frozen at -20°C	3 months
Frozen and thawed cycles	no more than 3 times

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel.
Plasma	K2-EDTA or Na-heparin
Urine	/

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips are recommended.
- Urine samples may show sediments after storage. Let stand or centrifuge the samples and use only the supernatant to perform the test.
- β2-MG is unstable in acidic conditions and degradation occurs at pH < 6 within 2 hours. It is recommended that urine samples with a pH value < 6.0 should be adjusted to pH 7-9 by the addition of 1 M NaOH as soon as possible after receipt.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 10 µL.

Specimen Storage

- Serum/Plasma: Specimens removed from the separator, red blood cells or clot may be stored up to 8 hours at 10-30°C or 7 days at 2-8°C, or 3 months frozen at -20°C. Frozen specimens subjected to up to 2 freeze/thaw cycles have been evaluated.
- Urine: Specimens may be stored up to 48 hours at 10-30°C or 7 days at 2-8°C, or 2 months frozen at -20°C. Frozen specimens subjected to up to 1 freeze/thaw cycle have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Samples, with β2-MG concentrations above the analytical measuring interval, can be diluted with Diluent by following manual dilution procedure. The recommended dilution ratio is 1:10. The concentration of the diluted sample must be >1.0 µg/mL.
- For manual dilution, multiply the result by the dilution factor. For dilution by the analyzers, the analyzer software automatically takes the dilution into account when calculating the sample concentration.

PROCEDURE

Materials Provided

β2-Microglobulin (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3, MAGLUMI X6, or Integrated System Biolumi 8000, Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

Preparation of the Reagent

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.
- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
- Execute recalibration according to the calibration interval required in this package insert.

Quality Control

- When new lot used, check or edit the quality control information.
- Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.

Sample Testing

- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: This method has been standardized against the WHO International Standard B2M.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.
- Every 28 days.
- The analyzer has been serviced.
- Control values lie outside the specified range.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published guidelines¹¹.

Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory's quality control procedures, quality control could be performed by running the β 2-Microglobulin assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi systems and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.

If the controls in kit are not enough for use, please order β 2-Microglobulin (CLIA) Controls (REF: 160201489MT) from Snibe or our authorized distributors for more.

RESULTS

Calculation

The analyzer automatically calculates the β 2-MG concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in μ g/mL. For further information please refer to the Analyzer Operating Instructions.

Interpretation of Results

The expected range for the β 2-Microglobulin assay was obtained by testing 1065 apparently healthy individuals in China, gave the following expected value:

Specimen Type	n	95 th percentile (μ g/mL)	Specimen Type	n	95 th percentile (μ g/mL)
Serum	540	≤ 2.1	Urine	525	≤ 0.15

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory establish its own reference interval.

LIMITATIONS

- Results should be used in conjunction with patient's medical history, clinical examination and other findings.
- If the β 2-MG results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- The assay is not suitable for screening of the general population.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies^{12,13}. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed¹⁴.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.

SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n = 180). The following results were obtained:

Sample	Mean (μ g/mL) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (μ g/mL)	%CV	SD (μ g/mL)	%CV	SD (μ g/mL)	%CV
Serum Pool 1	0.508	0.017	3.35	0.009	1.77	0.024	4.72
Serum Pool 2	2.155	0.052	2.41	0.016	0.74	0.076	3.53
Serum Pool 3	6.011	0.080	1.33	0.050	0.83	0.176	2.93
Plasma Pool 1	0.549	0.015	2.73	0.007	1.28	0.022	4.01
Plasma Pool 2	1.995	0.041	2.06	0.030	1.50	0.085	4.26
Plasma Pool 3	6.177	0.093	1.51	0.033	0.53	0.123	1.99
Urine Pool 1	0.549	0.016	2.91	0.007	1.28	0.026	4.74
Urine Pool 2	1.972	0.041	2.08	0.023	1.17	0.070	3.55
Urine Pool 3	6.224	0.095	1.53	0.033	0.53	0.150	2.41
Control 1	1.993	0.042	2.11	0.023	1.15	0.096	4.82
Control 2	6.022	0.082	1.36	0.061	1.01	0.118	1.96

Linear Range

0.030-10.0 μ g/mL (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

0.020-100 μ g/mL (defined by the Limit of Detection and the maximum of the master curve×Recommended Dilution Ratio).

Analytical Sensitivity

Limit of Blank (LoB) =0.005 μ g/mL.

Limit of Detection (LoD) =0.020 μ g/mL.

Limit of Quantitation (LoQ) =0.030 μ g/mL.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous

interferents in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within $\pm 10\%$. The following results were obtained:

Specimen Type	Interference	No interference up to	Interference	No interference up to
Serum	Hemoglobin	500 mg/dL	Rheumatoid factor	1500 IU/mL
	Intralipid	3000 mg/dL	Biotin	0.5 mg/dL
	Bilirubin	30 mg/dL	Total protein	5 g/dL
	HAMA	40 ng/mL	K2-EDTA	22.75 μ mol/mL
	ANA	398 AU/mL	Heparin sodium salt	80 IU/mL
Urine	Hemoglobin	500 mg/dL	Creatinine	5 mmol/L
	Intralipid	3000 mg/dL	Urea	350 mmol/L
	Bilirubin	30 mg/dL	Dextrose	5 mmol/L
	Total protein	5 g/dL	Sodium chloride	1000 mmol/L

Cross-Reactivity

Cross-reactivity was determined using the assay, three samples containing different concentrations of analyte were spiked with potential cross-reactant in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within $\pm 10\%$. The following results were obtained:

Specimen Type	Cross-reactant	No interference up to	Cross-reactant	No interference up to
Serum / Urine	IgG	3 g/dL	IgA	16 mg/mL
	IgM	5 mg/mL	IgE	500 μ g/mL

Method Comparison

A comparison of the β 2-Microglobulin assay with a commercially available immunoassay, gave the following correlations (μ g/mL):

Specimen Type	n	Passing-Bablok	Range of clinical specimen concentrations (μ g/mL)
Serum	316	$\hat{y}=0.9996x+0.0021$, $t=0.951$	0.031 – 9.96
Urine	117	$\hat{y}=0.9894x+0.0014$, $t=0.984$	0.033 – 9.92

REFERENCES

- Schardijn G, Van Eps L W S, Swaak A J G, et al. Urinary β 2-microglobulin in upper and lower urinary-tract infections[J]. The Lancet, 1979, 313(8120): 805-807.
- Turbat-Herrera E A. β 2-Microglobulin and the Kidney: An Overview[J]. Ultrastructural pathology, 1994, 18(1-2): 99-103.
- Zeng X, Hossain D, Bostwick D G, et al. Urinary β 2-Microglobulin is a sensitive indicator for renal tubular injury[J]. SAJ Case Rep, 2014, 1(1): 103.
- Astor B C, Muth B, Kaufman D B, et al. Serum β 2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation[J]. Kidney international, 2013, 84(4): 810-817.
- Woo K T, Lee E J C, Lau Y K, et al. Beta-2-microglobulin in the assessment of renal function of the transplanted kidney[J]. Nephron, 1985, 39(3): 223-227.
- Schardijn G H, Status van Eps L W. β 2-microglobulin: its significance in the evaluation of renal function[J]. Kidney international, 1987, 32(5): 635-641.
- Hermansen M L F, Hummelshoj L, Lundsgaard D, et al. Increased serum β 2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients[J]. Lupus, 2012, 21(10): 1098-1104.
- Cooper E H, Forbes M A, Hambling M H. Serum beta 2-microglobulin and C reactive protein concentrations in viral infections[J]. Journal of clinical pathology, 1984, 37(10): 1140-1143.
- Tasic V, Korneti P, Gucsev Z, et al. Atypical presentation of distal renal tubular acidosis in two siblings[J]. Pediatric Nephrology, 2008, 23(7): 1177-1181.
- Sandberg T, Cooper E H, Lidin-Janson G, et al. Fever and proximal tubular function in acute pyelonephritis[J]. Nephron, 1985, 41(1): 39-44.
- CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- Robert W. Schroff, Kenneth A. Foon, Shannon M. Beatty, et al. Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy[J]. Cancer Research, 1985, 45(2):879-885.
- Primus F J, Kelley E A, Hansen H J, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy[J]. Clinical Chemistry, 1988, 34(2):261-264.
- Boscato L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988, 34(1):27-33.

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8°C)		Use-by date
	Contains sufficient for<n> tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	<i>In vitro</i> diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.

Summary of safety and performance is available at Eudamed.

	Shenzhen New Industries Biomedical Engineering Co., Ltd. No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China Tel: +86-755-21536601 Fax:+86-755-28292740
	Shanghai International Holding Corp. GmbH (Europe) Eiffestrasse 80, 20537 Hamburg, Germany Tel: +49-40-2513175 Fax: +49-40-255726

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12

489 β 2-MG-en-EU, V1.0, 2021-12